Jan 31, 2019
Notice of Distribution of Retained Earnings
Name of listed company: | Chugai Pharmaceutical Co., Ltd. |
Code number: | 4519 (1st Section of Tokyo Stock Exchange) |
Head office: | 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo |
President & CEO: | Tatsuro Kosaka |
Inquiries to: | Masahiko Uchida, |
General Manager, Corporate Communications Dept. | |
Tel:+81-(0)3-3273-0881 |
Chugai Pharmaceutical Co., Ltd. announced that the Company resolved at the meeting of its Board of Directors held today to distribute retained earnings with the record date being December 31, 2018, as described below.
1. Contents of Dividends
Amount decided | Latest forecast for dividend (February 1, 2018) | Actual in the previous fiscal year (ended Dec. 31, 2017) | |
---|---|---|---|
Record date | December 31, 2018 | December 31, 2018 | December 31, 2017 |
Dividends per share | JPY55.00 | JPY31.00 | JPY33.00 |
Total dividends | JPY30,097 million | ― | JPY18,044 million |
Effective date | March 29, 2019 | ― | March 23, 2018 |
Dividend resource | Accumulated profit | ― | Accumulated profit |
2. Reasons for the Revision
Regarding income distribution, taking into account the strategic funding needs and earnings prospects, Chugai aims for a consolidated dividend payout ratio of 50% on average in comparison with Core EPS to provide a stable allocation of profit to all shareholders. In addition, internal reserves will be used to increase corporate value through investments to attain further growth in existing strategic domains and to identify future business opportunities.
In the fiscal year ended December 31, 2018, which is the final year of the medium-term business plan “IBI 18,” Chugai achieved the highest results in the past, which resulted in Core EPS increasing by 27.2% year-on-year and exceeding the officially announced forecast by 20.0%. At the same time, in comparison to the quantitative guidance of “IBI 18” – “achieving average annual growth in Core EPS (at the average constant exchange rate) at a low single digit (below 3% level),” Chugai achieved a result of 17.1% far above the goal. As it turned out, the group realized our goal of “becoming a "top pharmaceutical company."”
Reflecting the favorable results and based on our principles of “aiming a consolidated dividend payout ratio of 50% on average in comparison with Core EPS to provide a stable allocation of profit,” year-end dividends for the fiscal year ended December 31, 2018 are planned to be JPY55 per share, which is higher by JPY10 as increased regular dividend and JPY14 as special dividends than the forecast at the beginning of the fiscal year. As a result, total dividends for the fiscal year under review will be JPY86 per share, and the Core dividend payout ratio is 48.7% (an average of 48.6% for the past five years).
(For reference) Contents of annual dividends:
Dividend per share | |||
---|---|---|---|
End of second quarter | End of fiscal year | Total | |
Fiscal year ended Dec. 2018 |
JPY31.00 | JPY55.00 | JPY86.00 |
Fiscal year ended Dec. 2017 |
JPY29.00 | JPY33.00 | JPY62.00 |
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Tomoko Shimizu
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Toshiya Sasai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp